Literature DB >> 12734689

Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?

Elif Hindié1, Didier Mellière, Françoise Lange, Iyad Hallaj, Claire de Labriolle-Vaylet, Christian Jeanguillaume, Jacques Lange, Léon Perlemuter, Serge Askienazy.   

Abstract

Functioning pulmonary metastases are the most common distant lesions of differentiated thyroid cancer. About 50% of patients with such metastases die within 10 years. The impact of iodine-131 therapy is controversial. In this study we examined: (1) the early diagnostic value of post-surgery (131)I ablation for lung invasion and (2) the survival of patients receiving periodic (131)I therapy. Between January 1970 and December 1995 we provided initial treatment for 509 patients with thyroid cancer. Most of them (74%) underwent total thyroidectomy and (131)I ablation. Functioning pulmonary metastases occurred in 20 patients. All these patients received periodic (131)I therapy for as long as (131)I uptake persisted. Additional therapy consisted of lung surgery in three patients and local treatment of bone lesions in four patients. Follow-up data were recorded up to December 2001. Functioning pulmonary metastases occurred late in one patient, and were visible on the post-surgery (131)I therapy scan in the other 19 patients. At diagnosis of lung invasion, 11 patients had negative chest X-ray findings, and serum thyroglobulin levels were not suggestive of metastatic disease in 56% of these cases. One of the 11 patients with negative chest X-ray findings died with a neck recurrence, two have persistent pulmonary (131)I uptake, and the other eight are in apparent remission after receiving an average cumulative (131)I activity of 338 mCi (12.51 GBq). The nine patients with positive chest X-ray findings received an average of 939 mCi (34.74 GBq); two of them died, five are continuing to receive therapy and two are in apparent remission. Overall survival at 10 years is 84%. The average follow-up of the 17 survivors is 12.7 years. These results suggest that patients with functioning pulmonary metastases, even in advanced stages, may survive for many years on (131)I therapy. Early diagnosis, during post-surgery (131)I scanning, of radiologically inapparent metastases is associated with a better prognosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734689     DOI: 10.1007/s00259-003-1174-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  35 in total

Review 1.  Non-medical exposure to radioiodines and thyroid cancer.

Authors:  Elif Hindié; Laurence Leenhardt; Françoise Vitaux; Nicole Colas-Linhart; Pascale Grosclaude; Pierre Galle; André Aurengo; B Bok
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-07-19       Impact factor: 9.236

2.  Pulmonary metastases from thyroid carcinoma detectable only by 131 I scan. Treatment and response.

Authors:  J E Turner; G J Weir
Journal:  J Nucl Med       Date:  1972-11       Impact factor: 10.057

Review 3.  Sodium iodide symporter in health and disease.

Authors:  D H Shen; R T Kloos; E L Mazzaferri; S M Jhian
Journal:  Thyroid       Date:  2001-05       Impact factor: 6.568

4.  Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study.

Authors:  D Simon; C Körber; M Krausch; J Segering; P Groth; R Görges; F Grünwald; H W Müller-Gärtner; C Schmutzler; J Köhrle; H D Röher; C Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03-13       Impact factor: 9.236

5.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

Authors:  E L Mazzaferri; S M Jhiang
Journal:  Am J Med       Date:  1994-11       Impact factor: 4.965

6.  Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables.

Authors:  J J Ruegemer; I D Hay; E J Bergstralh; J J Ryan; K P Offord; C A Gorman
Journal:  J Clin Endocrinol Metab       Date:  1988-09       Impact factor: 5.958

7.  Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine.

Authors:  F Pacini; F Cetani; P Miccoli; F Mancusi; C Ceccarelli; F Lippi; E Martino; A Pinchera
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

8.  Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases.

Authors:  M Filesi; A Signore; G Ventroni; F F Melacrinis; G Ronga
Journal:  J Nucl Med       Date:  1998-09       Impact factor: 10.057

9.  The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients.

Authors:  N A Samaan; P N Schultz; R C Hickey; H Goepfert; T P Haynie; D A Johnston; N G Ordonez
Journal:  J Clin Endocrinol Metab       Date:  1992-09       Impact factor: 5.958

10.  Leukaemias and cancers following iodine-131 administration for thyroid cancer.

Authors:  F de Vathaire; M Schlumberger; M J Delisle; C Francese; C Challeton; E de la Genardiére; F Meunier; C Parmentier; C Hill; H Sancho-Garnier
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more
  18 in total

1.  Radioiodine therapy in patients with pulmonary metastases of thyroid cancer: when to treat, when not to treat?

Authors:  C Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07       Impact factor: 9.236

Review 2.  Radioiodine treatment of well-differentiated thyroid cancer.

Authors:  Leonard Wartofsky; Douglas Van Nostrand
Journal:  Endocrine       Date:  2012-06-26       Impact factor: 3.633

3.  On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer.

Authors:  Paolo Zanotti-Fregonara; Elif Hindié
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12       Impact factor: 9.236

4.  Clinico-pathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid carcinoma.

Authors:  Vivek Aggarwal; P R K Bhargav; Anjali Mishra; Gaurav Agarwal
Journal:  World J Surg       Date:  2007-01       Impact factor: 3.352

5.  A low thyroglobulin level cannot be used to avoid adjuvant 131I therapy after thyroidectomy for thyroid carcinoma.

Authors:  Paolo Zanotti-Fregonara; Gaia Grassetto; Elif Hindié; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02       Impact factor: 9.236

Review 6.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

Review 7.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

8.  Radioiodine treatment after surgery for differentiated thyroid cancer: a reasonable option.

Authors:  Jérôme Clerc; Frederik A Verburg; Anca M Avram; Luca Giovanella; Elif Hindié; David Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-06       Impact factor: 9.236

Review 9.  Standard and emerging therapies for metastatic differentiated thyroid cancer.

Authors:  Christine J O'Neill; Jennifer Oucharek; Diana Learoyd; Stan B Sidhu
Journal:  Oncologist       Date:  2010-02-08

10.  Difference of clinical and radiological characteristics according to radioiodine avidity in pulmonary metastases of differentiated thyroid cancer.

Authors:  Do-Hoon Kim; Ji-Hoon Jung; Seung Hyun Son; Choon-Young Kim; Chae Moon Hong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2013-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.